Acute Lymphoblastic Leukemia

• Brexucabtagene autoleucel (TECARTUS^®)  Kite Konnect^®, Kite, a Gilead Company

Bile Duct Cancer

• Pemigatinib (PEMAZYRE^®)  IncyteCARES

Bladder Cancer

• CoverOne^® (EMD Serono and Pfizer)

Bladder Cancer (Urothelial Cancer)

• erdafitinib (BALVERSA™) Janssen CarePath
• sacituzumab govetican-hziy (TRODELVY^®) TRODELVY Access Support (Gilead™)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

• Tagraxofusp (ELZONRIS^®) Stemline ARC^®, Stemline Therapeutics Inc., a Menarini Group Company

Bone Cancer

• Zoledronic acid (Zometa^®) Patient Assistance NOW Oncology (PANO) (Novartis Oncology)
• levoleucovorin for injection (KHAPZORY™)  Acrotech Specialty Therapy Access Resources (STAR^®) 

Breast Cancer

• sacituzumab govetican-hziy (TRODELVY^®) TRODELVY Access Support (Gilead™)

Breast Cancer (Early Stage)

• Oncotype DX Breast Recurrence Score® Oncotype DX Genomic Access Program (GAP)
• Oncotype DX® Breast DCIS Score™ Oncotype DX Genomic Access Program (GAP)

Chemotherapy-Induced Nausea and Vomiting (CINV)

• netupitant/fosnetupitant & palonosetron (AKYNZEO®)  Helsinn Cares

Chronic Graft Versus Host Disease

• Ibrutinib (IMBRUVICA^®) By Your Side Patient Support Pharmacyclics LLC and Janssen Biotech, Inc.

Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma

• Ibrutinib (IMBRUVICA^®) By Your Side Patient Support Pharmacyclics LLC and Janssen Biotech, Inc.
• Zanubrutinib (BRUKINSA^®) myBeiGene^® Patient Support

Colon Cancer

• Oncotype DX® Colon Recurrence Score™ Oncotype DX Genomic Access Program (GAP)
• levoleucovorin for injection (KHAPZORY™)  Acrotech Specialty Therapy Access Resources (STAR^®) 

Diffuse Large B-cell Lymphoma (DLBCL)

• Axicabtagene ciloleucel (YESCARTA^®)  Kite Konnect^®, Kite, a Gilead Company
• loncastuximab tesirine-lpyl (ZYNLONTA™) ADVANCING Patient Support | Personalized assistance from ADC Therapeutics

Endometrial Carcinoma

• Dostarlimab (​Jemperli)  GSK

Follicular Lymphoma

• Axicabtagene ciloleucel (YESCARTA^®)  Kite Konnect^®, Kite, a Gilead Company
• Zanubrutinib (BRUKINSA^®) myBeiGene^® Patient Support

Graft-versus-host disease (GVHD)

• Ruxolitinib (Jakafi^®)  IncyteCARES

Hepatocellular Carcinoma

• Lenvima (Lenvatinib^®) For the first-line treatment of patients with unresectable hepatocellular carcinoma --- Eisai Assistance Program
• cabozantinib tablets (CABOMETYX^®) Exelixis Access Services^® (EASE)

Kidney Cancer

• cabozantinib tablets (CABOMETYX^®) Exelixis Access Services^® (EASE)

Mantle Cell Lymphoma

• Zanubrutinib (BRUKINSA^®) myBeiGene^® Patient Support
• Brexucabtagene autoleucel (TECARTUS^®)  Kite Konnect^®, Kite, a Gilead Company

Marginal Zone Lymphoma

• Zanubrutinib (BRUKINSA^®) myBeiGene^® Patient Support

Merkel Cell Carcinoma

• CoverOne^® (EMD Serono and Pfizer)

Metastatic Breast Cancer

• HALAVEN^® (eribulin mesylate) injection, for intravenous use Eisai Assistance Program - Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.
• Cerianna™ (fluoroestradiol F 18) Injection GE HealthCare Pharmaceutical Diagnostics
• Elacestrant (ORSERDU^®) Stemline ARC^®, Stemline Therapeutics Inc., a Menarini Group Company

Multicentric Castleman's Disease

• Siltuximab (SYLVANT^®) Janssen CarePath

Multiple Myeloma

• Daratumumab (DARZALEX^®) Janssen CarePath
• Together with GSK Oncology
• isatuximab (Sarclisa)  Sanofi CareASSIST 
• melphalan for injection (EVOMELA^®)  Acrotech Specialty Therapy Access Resources (STAR^®) 
• dexamethasone tablets (HEMADY^®)  Acrotech Specialty Therapy Access Resources (STAR^®) 
• Daratumumab and hyaluronidase-fihj (DARZALEX FASPRO^®)  Janssen CarePath
• Talquetamab-tgvs (TALVEY™)  Janssen CarePath
• Teclistamab-cqyv (TECVAYLI®)  Janssen CarePath

Myelofibrosis

• Ruxolitinib (Jakafi^®)  IncyteCARES
• Momelotinib (​Ojjaara) GSK

Non-Hodgkin's Lymphomas

• ibritumomab tiuxetan injection (ZEVALIN^®)  Acrotech Specialty Therapy Access Resources (STAR^®) 

Non-Small Cell Lung Cancer

• Afatinib (GILOTRIF^®) Boehringer Ingelheim Solutions Plus™
• Amivantamab-vmjw (RYBREVANT^®)  Janssen CarePath

Ovarian Cancer

• Together with GSK Oncology

Peripheral T-Cell Lymphoma

• belinostat for injection (BELEODAQ^®)  Acrotech Specialty Therapy Access Resources (STAR^®) 
• pralatrexate injection (FOLOTYN^®)  Acrotech Specialty Therapy Access Resources (STAR^®) 

Polycythemia Vera

• Ruxolitinib (Jakafi^®)  IncyteCARES

Prevention and Treatment of Cancer-Related Infections

• Epoetin alfa (PROCRIT^®) Janssen CarePath

Prostate Cancer

• Apalutamide (ERLEADA^®)  Janssen CarePath
• sipuleucel-T (PROVENGE^®)  Dendreon on Call 
• Cabazitaxel (Jevtana)  Sanofi CareASSIST
• darolutamide (NUBEQA®) Access Services by Bayer^TM
• Abiraterone acetate (ZYTIGA^®)  Janssen CarePath
• Niraparib and abiraterone acetate (AKEEGA™)  Janssen CarePath

Prostate Cancer (Early Stage)

• Oncotype DX Genomic Prostate Score® Oncotype DX Genomic Access Program (GAP)

Prostate Cancer (with suspected metastasis who are candidates for initial definitive therapy)

• PYLARIFY^® (piflufolastat F 18) injection, for intravenous use Lantheus

Prostate Cancer (with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level)

• PYLARIFY^® (piflufolastat F 18) injection, for intravenous use Lantheus

Recurrent Breast Cancer

• Cerianna™ (fluoroestradiol F 18) Injection GE HealthCare Pharmaceutical Diagnostics

Renal Cell Carcinoma

• CoverOne^® (EMD Serono and Pfizer)
• Lenvima (Lenvatinib^®) For the first-line treatment of patients with unresectable hepatocellular carcinoma --- Eisai Assistance Program

Soft Tissue Sarcoma

• Trabectedin (YONDELIS^®) Janssen CarePath
• HALAVEN^® (eribulin mesylate) injection, for intravenous use Eisai Assistance Program - Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.

Thyroid Cancer

• Lenvima (Lenvatinib^®) For the first-line treatment of patients with unresectable hepatocellular carcinoma --- Eisai Assistance Program

Tumor Lysis Syndrome (TLS)

• rasburicase (Elitek)  SanofiCareASSIST

Waldenström's Macroglobulinemia

• Zanubrutinib (BRUKINSA^®) myBeiGene^® Patient Support
• Ibrutinib (IMBRUVICA^®) By Your Side Patient Support Pharmacyclics LLC and Janssen Biotech, Inc.